BioCardia, Inc. announced on July 16, 2025, that Henry Ford Health in Detroit, Michigan, has initiated patient enrollment for the company’s ongoing pivotal CardiAMP HF II trial. This expands the network of clinical sites participating in the study.
The CardiAMP HF II trial is evaluating the CardiAMP™ Cell Therapy Product for treating patients with ischemic heart failure of reduced ejection fraction (HFrEF) and elevated markers of cardiac stress. The addition of Henry Ford Health is expected to accelerate patient enrollment.
Dr. Gerald Koenig, a key investigator at Henry Ford Health, emphasized the importance of these trials for patients with ischemic heart failure who are in need of new therapies. This collaboration supports the company's goal of completing the trial efficiently.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.